Novo Nordisk AS (XTER:NOV) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:NOV Novo Nordisk AS XTER:NOV
79 GF Score
Price €40.71
GF Value €94.37
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk AS  (XTER:NOV) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novo Nordisk AS Cyclically Adjusted PB Ratio Related Terms


Novo Nordisk AS Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Cyclically Adjusted PB Ratio Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.79 40.65 54.23 41.70 17.96

Novo Nordisk AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.61 19.87 17.96 12.09 15.49

XTER:NOV vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PB Ratio falls into.


XTER:NOV
79GF Score
Novo Nordisk AS XTER:NOV
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novo Nordisk AS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Novo Nordisk AS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=6.671/122.9700*122.9700
=6.671

Current CPI (Jun. 2026) = 122.9700.

Novo Nordisk AS Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.088 100.200 1.335
201612 1.193 100.300 1.463
201703 1.062 101.200 1.290
201706 1.327 101.200 1.612
201709 1.285 101.800 1.552
201712 1.339 101.300 1.625
201803 1.221 101.700 1.476
201806 1.361 102.300 1.636
201809 1.322 102.400 1.588
201812 1.418 102.100 1.708
201903 1.328 102.900 1.587
201906 1.497 102.900 1.789
201909 1.500 102.900 1.793
201912 1.606 102.900 1.919
202003 1.552 103.300 1.848
202006 1.726 103.200 2.057
202009 1.722 103.500 2.046
202012 1.811 103.400 2.154
202103 1.704 104.300 2.009
202106 1.921 105.000 2.250
202109 1.942 105.800 2.257
202112 2.059 106.600 2.375
202203 1.968 109.900 2.202
202206 2.209 113.600 2.391
202209 2.281 116.400 2.410
202212 2.494 115.900 2.646
202303 2.386 117.300 2.501
202306 2.711 116.400 2.864
202309 2.788 117.400 2.920
202312 3.207 116.700 3.379
202403 2.973 118.400 3.088
202406 3.385 118.500 3.513
202409 3.632 118.900 3.756
202412 4.332 118.900 4.480
202503 4.180 120.200 4.276
202506 5.070 120.700 5.165
202509 5.123 121.600 5.181
202512 5.847 121.200 5.932
202603 6.122 121.680 6.187
202606 6.671 122.970 6.671

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Novo Nordisk AS (XTER:NOV) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €40.71 is trading 56.9% below its estimated GF Value™ of €94.37. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for XTER:NOV:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €94.37 vs. price of €40.71 (56.9% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the XTER:NOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score

Get the complete analysis for XTER:NOV

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.71
Price
€94.37
GF Value